• CONTACT
  • English
  • About
    • Company
    • Board of Directors
    • Officers
      • Dr. Steve Slilaty, Chief Executive Officer
      • Mr. Camille Sebaaly, Chief Financial Officer
      • Dr. Abderrazzak Merzouki, Chief Operating Officer
    • Auditor
    • Transfer Agent
    • Legal Counsel
  • Products on the market
    • Prescription drugs
    • OTC Products
    • Essential 9
  • Products in development
    • Generic drugs
    • Proprietary Drugs
  • Press releases
  • Investors
    • Stock Quote
    • SEC Filings
    • Quarterly Reports
    • Annual Reports
    • Corporate Governance
    • Committee charter
    • Auditor
    • Transfer Agent
    • Legal Counsel


SUNSHINE BIOPHARMA ENTERS INTO A COLLABORATION AGREEMENT WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT

by Sunshine Biopharma | Nov 16, 2022 | News

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a...

SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE

by Sunshine Biopharma | Oct 20, 2022 | News

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”), pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the...

SUNSHINE BIOPHARMA FILES ITS SECOND QUARTER REPORT WITH THE SEC

by Sunshine Biopharma | Aug 4, 2022 | News

Company Reports Significant Increase in Cash on Hand as a Result of Recent Financings Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and...

SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA

by Sunshine Biopharma | Jul 28, 2022 | News

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that...

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

by Sunshine Biopharma | Apr 28, 2022 | News

MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today...

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

by Sunshine Biopharma | Apr 26, 2022 | News

« Older Entries

Recent Posts

  • SUNSHINE BIOPHARMA ENTERS INTO A COLLABORATION AGREEMENT WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER mRNA PROJECT
  • SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE
  • SUNSHINE BIOPHARMA FILES ITS SECOND QUARTER REPORT WITH THE SEC
  • SEC Filing 10-Q | Second Quarter Report
  • SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA

Recent Comments

No comments to show.
6500 Trans-Canada Highway
4th Floor, Pointe-Claire,
Quebec H9R 0A5
CANADA

     514 426-6161

     info@sunshinebiopharma.com

     514 426-6161

© SUNSHINE BIOPHARMA INC. All rights reserved.